Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Health surveillance data

Currently viewing:

Administrative data

health surveillance data
Adequacy of study:
key study
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Meets generally accepted scientific standards, well documented and acceptable for assessment

Data source

No information
Sadove MS, Wyant GM, and Cletcher JO (1955). Ethyl vinyl|ether: Pharmacological and clinical evaluation. Curr. Res.|Anaesth. Analg. 34 (4), 235-240.

Materials and methods

Study type:
human medical data

Test material

Constituent 1
Chemical structure
Reference substance name:
Ethyl vinyl ether
EC Number:
EC Name:
Ethyl vinyl ether
Cas Number:
Molecular formula:

Results and discussion

Any other information on results incl. tables

Following pharmacological animal studies in the end 1940s
EVE was first administered to a human being in 1947.
Thereafter it was used in large series for the induction of
anesthesia in children.

In the animal studies, EVE did not significantly change
blood pressure, Electrocardiogram (ECG),
Electroencephalogram (EEG), blood urea, carbon dioxide
combining power. There was no hemolysis. Clotting time was
increased by 10-15%. Liver function was normal, and there
were no pathological changes noted in liver and kidney.

Clinical properties of EVE as an anesthetic in humans:

Induction: rapid
Maintenance: easy
Irritation: slight
Salivary excretion: marked
Relaxation: fair
Running movements: occur
Emergence Not likely
Nausea and vomiting: fairly common

The pharmacological effects were studied in 29 patients,
aged 14 to 58 years (7 males, 22 females). Gynecological and
orthopedic cases prevailed. EVE was used in combination with
other common anesthetics. In brief, findings were as
Liver function was unchanged in 58% of the patients.
Bromsulphthalein excretion was observed in some cases. In
two of these, large doses up to 110 ml EVE had been used.
Urinalysis: no changes were noted in 68% of the patients.
Six patients (20%) showed findings (traces of acetone (n=6),
increased sugar (n=2), traces of albumin (n=3) which had
returned to normal on day 5 post treatment.
Blood: no changes in 82% of the patients; the remainder
showed slight leucocytosis.
ECG: no change in 48% of the patients. Tachycardia,
auricular and ventricular premature contractions were all
seen. Mild myocardial depression was noted in 5 cases (17%).

Nausea, vomiting: was seen in 10 out of 29 patients.
Salivation: was quite severe at times; was treatable with

Applicant's summary and conclusion

The authors concluded that EVE was a useful and in many
respect a safer anesthetic in children than divinylether.